ND Capital led a $30.7m Series A round in Vandria.

ND Capital, a venture capital firm, led a $30.7m Series A round in Vandria, a biopharmaceutical company, with participation from Hevolution Foundation and Dolby Family Ventures. “We are excited by the potential of mitophagy as a new therapeutic approach with strong disease-modifying effects for an aging world population that faces cognitive impairment, Alzheimer’s and Parkinson’s disease. Vandria’s pipeline offers even wider potential to address other age-related and chronic diseases of the muscle, lung and liver. This investment aligns with our mission to fund innovations that help catalyse the shift from lifespan to healthspan so that everyone can live healthier lives for longer,” Jens Eckstein, Hevolution Foundation Investment Partner.